TY - JOUR
T1 - Diabetes management in chronic kidney disease
T2 - Synopsis of the 2020 kdigo clinical practice guideline
AU - Navaneethan, Sankar D.
AU - Zoungas, Sophia
AU - Caramori, M. Luiza
AU - Chan, Juliana C.N.
AU - Heerspink, Hiddo J.L.
AU - Hurst, Clint
AU - Liew, Adrian
AU - Michos, Erin D.
AU - Olowu, Wasiu A.
AU - Sadusky, Tami
AU - Tandon, Nikhil
AU - Tuttle, Katherine R.
AU - Wanner, Christoph
AU - Wilkens, Katy G.
AU - Lytvyn, Lyubov
AU - Craig, Jonathan C.
AU - Tunnicliffe, David J.
AU - Howell, Martin
AU - Tonelli, Marcello
AU - Cheung, Michael
AU - Earley, Amy
AU - Rossing, Peter
AU - de Boer, Ian H.
AU - Khunti, Kamlesh
N1 - Publisher Copyright:
© 2021 American College of Physicians. All rights reserved.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - Description: The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed a clinical practice guideline in 2020 for the management of patients with diabetes and chronic kidney disease (CKD). Methods: The KDIGO Work Group (WG) was tasked with developing the guideline for diabetes management in CKD. It defined the scope of the guideline, gathered evidence, determined systematic review topics, and graded evidence that had been summarized by an evidence review team. The English-language literature searches, which were initially done through October 2018, were updated in February 2020. TheWGused the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to appraise evidence and rate the strength of the recommendations. Expert judgment was used to develop consensus practice points supplementary to the evidence-based graded recommendations. The guideline document underwent open public review. Comments from various stakeholders, subject matter experts, and industry and national organizations were considered before the document was finalized. Recommendations: The guideline includes 12 recommendations and 48 practice points for clinicians caring for patients with diabetes and CKD. This synopsis focuses on the key recommendations pertinent to the following issues: Comprehensive care needs, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and educational and integrated care approaches.
AB - Description: The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed a clinical practice guideline in 2020 for the management of patients with diabetes and chronic kidney disease (CKD). Methods: The KDIGO Work Group (WG) was tasked with developing the guideline for diabetes management in CKD. It defined the scope of the guideline, gathered evidence, determined systematic review topics, and graded evidence that had been summarized by an evidence review team. The English-language literature searches, which were initially done through October 2018, were updated in February 2020. TheWGused the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to appraise evidence and rate the strength of the recommendations. Expert judgment was used to develop consensus practice points supplementary to the evidence-based graded recommendations. The guideline document underwent open public review. Comments from various stakeholders, subject matter experts, and industry and national organizations were considered before the document was finalized. Recommendations: The guideline includes 12 recommendations and 48 practice points for clinicians caring for patients with diabetes and CKD. This synopsis focuses on the key recommendations pertinent to the following issues: Comprehensive care needs, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and educational and integrated care approaches.
UR - http://www.scopus.com/inward/record.url?scp=85101244238&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101244238&partnerID=8YFLogxK
U2 - 10.7326/M20-5938
DO - 10.7326/M20-5938
M3 - Review article
C2 - 33166222
AN - SCOPUS:85101244238
SN - 0003-4819
VL - 174
SP - 385
EP - 394
JO - Annals of internal medicine
JF - Annals of internal medicine
IS - 3
ER -
